Flora, Darcy R.
Evens, Andrew M.
Liu, Nicholas
Yu, Kristina S.
Byrd, Rachel
Fanale, Michelle A.
Holmes, Katherine
Flores, Carlos
Surinach, Andy
Parsons, Susan K.
Funding for this research was provided by:
Seagen Inc.
Article History
Received: 11 May 2023
Accepted: 15 October 2023
First Online: 2 November 2023
Declarations
:
: This study was conducted in full compliance with the Guidelines for Good Pharmacoepidemiology Practices published by the International Society of Pharmacoepidemiology (ISPE) and the laws and regulations of the country in which the research was conducted. This study was reviewed by the New England IRB and received exemption status.
: Not applicable.
: Not applicable.
: <b>Darcy R. Flora</b>This author is an employee of and in a leadership role at Gryt Health, which received funding from Seagen Inc. to conduct this work.Stock and Other Ownership Interests: Gryt Health.<b>Andrew M. Evens</b>Grant/Research Support: ORIEN and Leukemia & Lymphoma Society, NIH/NCI.Consulting or Advisory Role: Seagen Inc., Hutchmed, Incyte, Epizyme, Research to Practice, Curio, Cota, Patient Power, Curio Science, OncLive, Novartis, AbbVie, and Pharmacyclics.<b>Nicholas Liu</b>Employment: Seagen Inc.Stock and Other Ownership Interests: Seagen Inc.<b>Kristina S. Yu</b>Employment: Seagen Inc.Stock and Other Ownership Interests: Seagen Inc.<b>Rachel Byrd</b>This author is an employee of Gryt Health, which received funding from Seagen Inc. to conduct this work.<b>Michelle A. Fanale</b>Employment: Seagen Inc.Stock and Other Ownership Interests: Seagen Inc.<b>Katherine Holmes</b>The author declares no competing interests.<b>Carlos Flores</b>The author declares no competing interests.<b>Andy Surinach</b>Consulting or Advisory Role: Seagen Inc.<b>Susan K. Parsons</b>Grant/Research Support: Leukemia & Lymphoma Society and NIH/NCI.Consulting or Advisory Role: Seagen Inc.